<DOC>
	<DOCNO>NCT00523718</DOCNO>
	<brief_summary>Obsessive-compulsive disorder ( OCD ) affect 2-3 % population lead great deal suffer . Many patient benefit establish treatment , mainstay cognitive behavioral therapy group antidepressant medication know serotonin reuptake inhibitor . However , 20-30 % patient get minimal benefit establish therapeutic strategy . New avenue treatment urgently need . Existing medication obsessive-compulsive disorder affect neurotransmitter serotonin dopamine ; increase evidence suggest functional disruption different neurotransmitter , glutamate , may contribute case OCD . The investigator therefore interested use medication target glutamate novel treatment option OCD patient benefit establish treatment . One medication drug riluzole , FDA approve amyotrophic lateral sclerosis ( ALS ) , Lou Gehrig 's disease , may benefit patient psychiatric disorder due ability moderate excessive glutamate . In preliminary study , investigator treat patient riluzole ( addition establish pharmacological regimen ) open-label fashion ( , without placebo-treated control group ) , investigator find 40-50 % patient substantially improve 2-3 month . While immensely promising , preliminary study prove riluzole truly new beneficial medication treatment OCD ; rigorous placebo-controlled trial need purpose . The investigator therefore recruit patient participate double-blind , placebo-controlled trial riluzole , add whatever OCD medication take .</brief_summary>
	<brief_title>Riluzole Augmentation Treatment-refractory Obsessive-compulsive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Diagnostic Statistical Manual Mental Disorders IV ( DSMIV ) diagnosis OCD , confirm Structured Clinical Interview DSMIV ( SCIDIV ) ; symptom least 1 year duration moderate severe OCD symptom measure score YaleBrown ObsessiveCompulsive Scale ( YBOCS ) 16 great document failure adequate trial selective serotonin reuptake inhibitor ( SSRI ) agreement engage reliable form birth control ( woman ) primary diagnosis psychotic disorder active substance abuse dependence unstable medical condition prior exposure riluzole prior psychosurgery pregnancy , breastfeeding , intent become pregnant study liver function test ( LFTs ) elevate 2x upper limit normal evidence active liver disease seizure disorder active suicidal ideation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>obsessive-compulsive disorder</keyword>
	<keyword>OCD</keyword>
	<keyword>glutamate</keyword>
	<keyword>riluzole</keyword>
	<keyword>augmentation</keyword>
	<keyword>treatment</keyword>
</DOC>